Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International Journal of Cardiology

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJCARD.2004.02.013PMID 15771921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

  2003cited by this paper
• Use of biomarkers in the management of heart failure: are we there yet?

  2003cited by this paper
• Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis

  2003cited by this paper
• Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure

  2002cited by this paper
• Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

  2002cited by this paper
• brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.

  2002cited by this paper
• A glossary of circulating cytokines in chronic heart failure

  2001cited by this paper
• Inotropic therapy for heart failure: an evidence-based approach.

  2001cited by this paper
• A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

  2001cited by this paper
• A rapid bedside test for B‐type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure

  2000cited by this paper
• Myocardial efficiency during levosimendan infusion in congestive heart failure

  2000cited by this paper
• High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.

  2000cited by this paper
• New insights into the pathophysiological role for cytokines in heart failure.

  1999cited by this paper
• Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments.

  1998cited by this paper
• Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

  1998cited by this paper
• Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

  1997cited by this paper
• The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes.

  1997cited by this paper
• Circulating interleukin-6 in severe heart failure.

  1997cited by this paper
• Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation

  1995cited by this paper

• Comparative safety and efficacy of levosimendan versus dobutamine in acute heart failure: a systematic review, meta-analysis, and meta-regression

  2026cites this paper
• Serum concentrations of levosimendan and its metabolites OR-1855 and OR-1896 in cardiac surgery patients with cardiopulmonary bypass

  2024cites this paper
• The Impact of Inotropes and Vasopressors on Cerebral Oxygenation in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage: A Narrative Review

  2024cites this paper
• The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

  2023cites this paper
• The effects of levosimendan in patients undergoing transcatheter aortic valve replacement- a retrospective analysis

  2022cites this paper
• Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance

  2021cites this paper
• The assesment of the cardioprotective effectiveness of levosimendan on patients with impaired left ventricle functions and less than %40 of ejection fraction who will receive coronary artery bypass graft operation

  2020cites this paper
• Hepatic encephalopathy and cirrhotic cardiomyopathy in Intensive Care Unit.

  2018cites this paper
• Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension

  2018cites this paper
• Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

  2016cites this paper
• Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial

  2016cites this paper
• Five-year mortality in cardiac surgery patients with low cardiac output syndrome treated with levosimendan: prognostic evaluation of NT-proBNP and C-reactive protein.

  2016cites this paper
• Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.

  2015cites this paper
• Levosimendan and organic protection

  2015cites this paper
• Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro

  2014cites this paper
• Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials

  2014cites this paper
• Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery.

  2013cites this paper
• Intermittent levosimendan treatment in patients with severe congestive heart failure

  2013cites this paper
• Identification of Inflammatory Mediators and Their Modulation by Strategies for the Management of the Systemic Inflammatory Response During Cardiac Surgery

  2012cites this paper
• Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan.

  2012cites this paper
• Intermittent Levosimendan Infusions in Advanced Heart Failure: Favourable Effects on Left Ventricular Function, Neurohormonal Balance, and One-Year Survival

  2012cites this paper
• Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?

  2012cites this paper
• Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.

  2012cites this paper
• Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment.

  2012cites this paper
• Per-operative levosimendan use in high-risk patients undergoing coronary artery bypass surgery

  2012cites this paper
• PerOperative Levosimendan Use In HighRisk Patients Undergoing Coronary Artery Bypass Surgery Yüksek Riskle Koroner Arter Cerrahisi Uygulanan Hastalarda PerOperatif Levosimendan Kullanimi

  2012cites this paper
• Levosimendan

  2012cites this paper
• Efeitos do levosimendan sobre TNF-alfa, PNB e MMP-1 em pacientes com insuficiência cardíaca com anemia

  2012cites this paper
• TRATAMENTO DA INSUFICIÊNCIA CARDÍACA AGUDA NOVOS FÁRMACOS

  2011cites this paper
• Levosimendan in the treatment of cardiogenic shock.

  2010cites this paper
• Biomarkers of Cardiac Injury

  2010cites this paper
• New investigational drugs for the management of acute heart failure syndromes.

  2010cites this paper
• Tratamiento de la depresión miocárdica por sepsis con levosimendan. Serie de casos y revisión de la bibliografía

  2010cites this paper
• Doppler imaging predicts cardiac events in chronic pulmonary thromboembolism.

  2009cites this paper
• Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: a preliminary report.

  2009cites this paper
• Right atrium contractility and right ventricular diastolic function assessed by pulsed tissue Doppler imaging can predict brain natriuretic peptide in adults with acquired pulmonary hypertension.

  2009cites this paper
• Investigational positive inotropic agents for acute heart failure.

  2009cites this paper
• Modulating the levels of circulating BNP by therapeutic approaches for heart failure

  2009cites this paper
• Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.

  2008cites this paper
• In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts.

  2008cites this paper
• Most frequently cited and downloaded papers from volumes 99 and 100

  2008cites this paper
• Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.

  2008cites this paper
• Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.

  2008cites this paper
• Effects of levo‐ and dextrosimendan on NF‐κB‐mediated transcription, iNOS expression and NO production in response to inflammatory stimuli

  2008influential citation
• Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.

  2008cites this paper
• Levosimendan-induced reduction in natriuretic peptide levels during the treatment of decompensated heart failure: Clinical implications — Reply

  2008influential citation
• Novel biologic mechanisms of levosimendan and its effect on the failing heart

  2008cites this paper
• Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty.

  2008cites this paper
• Levosimendan: beyond its simple inotropic effect in heart failure.

  2007influential citation
• Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity.

  2007cites this paper
• Clinical Pharmacology of Levosimendan

  2007cites this paper
• 25 years at the International Journal of Cardiology — What has changed and what hasn't

  2007cites this paper
• The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure

  2007cites this paper
• Classical inotropes and new cardiac enhancers

  2007influential citation
• Top downloads from the International Journal of Cardiology entering 2006

  2006cites this paper
• New Inotropic Agent-Levosimendan

  2006cites this paper
• Efficacy and Safety of Intermittent, Long-term, Concomitant Dobutamine and Levosimendan Infusions in Severe Heart Failure Refractory to Dobutamine Alone

  2006cites this paper
• Clinical significance of acute neurohormonal response after levosimendan treatment.

  2006cites this paper
• Evidence-based use of levosimendan in different clinical settings.

  2006cites this paper
• Levosimendan, a New Inotropic and Vasodilator Agent

  2006cites this paper
• Ascending aortic puncture during percutaneous balloon mitral valvuloplasty

  2006cites this paper
• Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure

  2006cites this paper
• Cardiac Natriuretic Hormone System as Target for Cardiovascular Therapy

  2006cites this paper
• A review of levosimendan in the treatment of heart failure

  2006cites this paper
• Levosimendan and plasma BNP levels: Do inflammatory cytokines regulate BNP in chronic decompensated heart failure?

  2006influential citation
• Levosimendan therapy in decompensated chronic heart failure: Favourable haemodynamic and neurohormonal effects but for how long?

  2006cites this paper
• Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.

  2005cites this paper
• The challenge of acute heart failure syndromes.

  2005cites this paper
• Levosimendan therapy in decompensated chronic heart failure : Effects on natriuretic peptides and hemodynanic parameters

  2005cites this paper
• European experience on the practical use of levosimendan in patients with acute heart failure syndromes.

  2005cites this paper
• Levosimendan for the treatment of acute heart failure syndromes

  2005cites this paper
• Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure

  2005cites this paper
• Letter to the Editor Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure

  2005cites this paper
• Randomized clinical trials with levosimendan.

  2005cites this paper